Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CNKSR1 | Q969H4 | 5/20 | 0.44 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653275 | 0.89 | HIF1A (0.51) | MEN1KMT2AMAPTNPSR1HIF1A | |
| SCHEMBL1651516 | 0.88 | MEN1 (0.46) | MEN1KMT2AMAPTNPSR1HIF1A | |
| SCHEMBL1655516 | 0.86 | BRAF (0.46) | MEN1KMT2AALDH1A1HPGDBRD4 | |
| SCHEMBL1654112 | 0.86 | BCL2A1 (0.45) | MEN1KMT2AMAPTNPSR1HIF1A | |
| SCHEMBL1653948 | 0.85 | ALDH1A1 (0.52) | MEN1KMT2AMAPTNPSR1HIF1A | |
| SCHEMBL2661325 | 0.84 | CDK1 (0.39) | MEN1KMT2AMAPTNPSR1ALDH1A1 | |
| SCHEMBL1653957 | 0.83 | MEN1 (0.48) | MEN1KMT2AMAPTNPSR1HIF1A | |
| SCHEMBL1652707 | 0.82 | CNKSR1 (0.47) | MEN1KMT2AMAPTNPSR1HIF1A | |
| SCHEMBL1653068 | 0.81 | MEN1 (0.46) | MEN1KMT2AMAPTNPSR1HIF1A | |
| SCHEMBL1653471 | 0.80 | SMN1; SMN2 (0.50) | MEN1KMT2AMAPTNPSR1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957070-B2 | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957070-B2 | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957070-B2 | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-1873144-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-1873144-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8410087-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| EP-2508524-A2 | Indole compound | Takeda Pharmaceutical Company Limited (JP) | 2012-10-10 | — | — | EP | disclosed |
| EP-2308839-A1 | Fused heterocyclic compounds | Takeda Pharmaceutical Company Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7777047-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20100144702-A1 | INDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| US-7652133-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090286975-A1 | Indole compound | YASUMA TSUNEO | 2009-11-19 | — | — | US | disclosed |
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-2074119-A1 | INDOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008050821-A1 | INDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| US-20080096877-A1 | Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1873144-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
| EP-1873144-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247746-A1 | Fused heterocyclic compound | GCKR, GCK, GPR119 | MEN1 2880/4885KMT2A 1020/4885MAPT 4377/4885 |
| US-20100144702-A1 | INDOLE COMPOUND | GCKR, GPR119, SLC5A1 | MEN1 2138/4885KMT2A 507/4885MAPT 4224/4885 |
| US-20090286975-A1 | Indole compound | GCKR, GPR119, SLC5A1 | MEN1 2138/4885KMT2A 507/4885MAPT 4224/4885 |
| US-20080096877-A1 | Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example | GCKR, GCK, KHK | MEN1 3693/4885KMT2A 520/4885MAPT 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.